Investors Chronicle
Boardroom Talk: Summit Therapeutics' long road to drug approval
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:14:14
- Mas informaciones
Informações:
Sinopsis
Summit Therapeutics is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates. See acast.com/privacy for privacy and opt-out information.